We are delighted that our Chief Medical Officer Dr Catherine Calderwood as provided us with some thoughtful reading and indeed future horizons which cover both screening and prevention.
European position statement on lung cancer screening (Oudkerk et al) https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30861-6/fulltext
Lung cancer screening with low-dose CT has been a contentious issue for some years. This European Union (EU) position statement finally represents a consensus view representing the views of the leading EU specialists in the field. This paper presents the available evidence and the major issues that need to be addressed to ensure the successful implementation of low-dose CT lung cancer screening in Europe. This statement identified specific actions required by the European lung cancer screening community to adopt before the implementation of low-dose CT lung cancer screening. Given the potential cost of such programmes in each nation, this paper represents a stark challenge to NHS organisations in this country. It proposes that planning for implementation of low-dose CT screening should start throughout Europe as soon as possible. Guidelines, standard indicators of performance, training of dedicated radiologists and professionals and a comprehensive quality assurance system would have to be put in place in European countries to implement national public health screening programs
Main take home messages;
Lung cancer screening will be difficult and numerous parameters of any screening program need to be carefully assessed and agreed these include;
- modality for selection of high risk subjects and recruitment,
- integration of screening and smoking cessation,
- optimal screening regimen and related research on biomarkers,
- informed decision making, promotion of primary prevention and how screening is integrated with smoking cessation,
- screening must be a part of a comprehensive risk reduction policy.